Cell and Gene Therapy Product Approvals in China: Insights into Clinical Trials and Regulatory Advances

This study undertook a comprehensive analysis to assess China's progress in the approval of cell and gene therapy products (CGTPs). It provided insights into clinical trials and regulatory advancements by examining the approval characteristics, pivotal clinical trials, expedited programs, orphan designations, development and review timelines, and drug lags through a comparative analysis across four regions: the United States, the European Union, Japan, and China. The findings indicated that China had achieved substantial advancements in the approval of CGTPs in recent years. This progress was evidenced by a year-over-year increase in the number of approvals, a flexible authorization approach utilizing surrogate endpoints and single-arm trials, support for product launches through various expedited programs, and the shortest development timelines among the four regions analyzed. Nevertheless, when compared to the United States, European Union, and Japan, China faced several challenges in the approvals for CGTPs. Notably, the therapeutic area is predominantly in oncology, with the market largely concentrated domestically. Two aspects to be highlighted were that the orphan designation was lacking as well as the implementation of multi-regional clinical trials (MRCTs) in pivotal clinical trials. Furthermore, the progression of post-marketing confirmatory trials was sluggish and lacked robust oversight mechanisms. The expedited programs supporting the CGTP approvals required optimization concerning categories and applications. Additionally, the review timelines had not demonstrated a competitive advantage, and the drug lags were the longest across the four regions. It is imperative for regulatory authorities to take proactive measures to mitigate any deficiencies resulting from the identified challenges.